Orgenesis stock tracks its cell therapy platform

Orgenesis stock follows a business tied to point-of-care cell therapy and related manufacturing services. The company is listed on Nasdaq and remains a small-cap healthcare name.

By Christina Vaughn, Background & Management desk. Reviewed on July 3, 2026 at 2:39 p.m. ET.

Orgenesis Inc (US68621F1021) is a Nasdaq-listed healthcare company built around point-of-care cell therapy and manufacturing services. The stock sits within a sector where funding, clinical execution and partner activity can matter more than a single headline catalyst.

Business model first

Orgenesis describes itself as a company focused on therapies and technologies that support decentralized cell and gene treatment production. That model ties the shares to a mix of clinical development, platform adoption and capital requirements.

Market context

For US investors, the important anchor is the Nasdaq listing and the healthcare backdrop. Small-cap biotech and platform names often trade on expectations around execution rather than near-term earnings power.

What the company sells

The core story centers on a therapeutic and manufacturing platform rather than a single consumer product. In that sense, the company's value case depends on whether its technology can support broader clinical and commercial use.

Stock check

As of July 3, 2026, 2:39 p.m. ET, a live price was not included in the available search results for this call. The company remains a Nasdaq-listed small-cap healthcare name.

Fact box

• Company: Orgenesis Inc
• ISIN: US68621F1021
• Ticker: ORGS
• Exchange: Nasdaq
• Price (as of July 3, 2026, 2:39 p.m. ET): not available in the provided search results
• Sector / Industry: Healthcare / Biotechnology

This article was generated automatically and technically reviewed before publication. Market prices, analyst data and company information are provided without warranty and may change at short notice. This content is for informational purposes only and is not investment, financial, legal or tax advice. It is not a recommendation to buy or sell any security. Investing in securities involves risk, including the possible loss of principal.